Measuring neuromelanin using MRI

Withdrawn

• Conditions: Parkinson's disease; pscyhosis; schizophrenia; 10028037; 10039628

• Registration Number: NL-OMON45255
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

Patients with schizofrenia/psycosis:
* clinical diagnosis schizophrenia or schizophreniphorm disorder or psychotic episode;Patients with Parkinson's disease
* clinical diagnosis Parkinson's disease, strong indication of Parkinson's disease or Parkinsonian symptoms;Healthy controls:
* age- and gender matched with patients at group level;All participants:
* Capacity to understand the study and to sign *informed consent*.

Exclusion Criteria

Healthy controls:
* Severe neurologic and psychiatric disorders
* Use of psychotropic drugs or drugs of abuse that may influence the dopamine system;All participants:
- contra-indications for MRI (including pacemaker, ferromagnetic implants, possibility of iron splinters in the orbita, claustrophobia )
- pregnancy

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The difference between patients and healthy controls in neuromelanin<br /><br>concentration (or indirect quantitative measure or this) in the substantia<br /><br>nigra and locus coeruleus.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Correlations between neuromelanin concentrations (or indirect quantitative<br /><br>measure or this) in the substantia nigra or locus coeruleus and therapy<br /><br>resistance or side effects of therapy (such as extrapyramidal symptoms).</p><br>